C. Dromain

Discipline

Economies et finances (1)

Type de document

Articles (8) Recensions (2)

Co-auteur

Date

Source

Mot-clé

Treatment (8) Patients (8) Patients (8) maladie (6) maladie (6) thérapie (5) Tumors (5) Therapeutics (5) Immunotherapy (5) Immunotherapy (5) Human beings (4) Evaluation (4) Cancer (4) Tumors (4) évaluation (3) survie (3) Inhibitors (3) Survival (3) Melanoma (3) Imaging (3) Evaluation (3) tumeur (2) risque (2) papier (2) oncologie (2) infiltration (2) analyse (2) cancer (2) taux (2) Diagnosis (2)

Documents écrit par C. Dromain (8) | parle de C. Dromain (0)

European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours.
A. Rinke et al.
Preoperative hiatal hernia in esophageal adenocarcinoma; does it have an impact on patient outcomes?
P. St-Amour et al.
Estimated Costs of the Ipilimumab-Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma.
B. Gautron Moura et al. (21 déc. 2022)
First communication on the efficacy of combined 177Lutetium-PSMA with immunotherapy outside prostate cancer.
A. Digklia et al.
Tumor response assessment on imaging following immunotherapy.
A.M. Berz et al. (2022)
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
F.G. Herrera et al.
Imaging of tumour response to immunotherapy.
C. Dromain et al. (3 janv. 2020)
Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.
C. Dromain et al. (14 janv. 2019)